Connect with us

Published

on

Verily headquarters in San Bruno, California.

Courtesy: Verily

Verily is selling its stop-loss insurance subsidiary, Granular Insurance Company, to the insurance provider Elevance Health, the Alphabet health tech company confirmed to CNBC on Thursday.

Verily is one of Google’s sister companies and operates within Alphabet’s “Other Bets” category. The Granular sale is the latest in a series of sweeping changes at the precision health company, which has slashed its workforce, restructured its business and overhauled its executive leadership in recent years.

The terms of the deal were not disclosed. 

Verily launched Granular, initially called Coefficient Insurance Company, in 2020 with financial backing from the commercial insurance unit of the Swiss Re Group. The business offered self-funded employers and captives medical stop-loss, fronting reinsurance and fronting solutions that used “proprietary technology,” Verily said.

Alphabet’s health company has raised more than $1 billion, and it has attracted big-name talent. Apple’s former head of health strategic initiatives, Myoung Cha, joined Verily as chief product officer last year, and Andrew Trister, Verily’s chief medical and scientific officer, was a founding member of Apple’s health team. Amy Abernethy, who served as principal deputy commissioner at the U.S. Food and Drug administration, joined the company in 2021 before departing in late 2023. 

But Verily has struggled to find and stick to a winning niche in health care. 

The company started as a moonshot in 2015 within Alphabet’s innovation lab X, formerly Google X, where it developed hardware like continuous glucose monitors. Verily pivoted to pandemic response when Covid-19 broke out in 2020, and it switched directions again to focus on precision medicine in 2022.

Verily introduced a new artificial intelligence-powered chronic care solution in June called Lightpath. The first offering is metabolic health focused, and it will support patients taking the blockbuster weight loss medications called GLP-1s, using continuous glucose monitors or other interventions, according to a release.

And now, the company is getting out of the insurance business.

Elevance Health did not immediately respond to CNBC’s request for comment. The deal was first reported by Business Insider.

Watch: Alphabet shares sink after mixed Q4 results

Alphabet shares sink after mixed Q4 results

Continue Reading

Technology

Broadcom and Costco’s rich valuations leave little room for error as battleground stocks

Published

on

By

Broadcom and Costco's rich valuations leave little room for error as battleground stocks

Continue Reading

Technology

ServiceNow in talks to acquire cybersecurity startup Armis in potential $7 billion deal, Bloomberg reports

Published

on

By

ServiceNow in talks to acquire cybersecurity startup Armis in potential  billion deal, Bloomberg reports

Software company ServiceNow is in advanced talks to buy cybersecurity startup Armis, which was last valued at $6.1 billion, Bloomberg reported

The deal, which could reach $7 billion in value, would be ServiceNow’s largest acquisition, the outlet said, citing people familiar with the situation who asked not to be identified because the talks are private. 

The acquisition could be announced as soon as this week, but could still fall apart, according to the report. 

Armis and ServiceNow did not immediately return a CNBC request for comment.

Armis, which helps companies secure and manage internet-connected devices and protect them against cyber threats, raised $435 million in a funding round just over a month ago and told CNBC about its eventual plans for an IPO.

Armis CEO Yevgeny Dibrov and CTO Nadir Izrael.

Courtesy: Armis

CEO and co-founder Yevgeny Dibrov said Armis was aiming for a public listing at the end of 2026 or early 2027, pending “market conditions.” 

Armis’s decision to be acquired rather than wait for a public listing is a common path for startups at the moment. The IPO markets remain choppy and many startups are choosing to remain private for longer instead of risking a muted debut on the public markets. 

Founded in 2016, Armis said in August it had surpassed $300 million in annual recurring revenues, a milestone it achieved less than a year after reaching $200 million in ARR.

Its latest funding round was led by Goldman Sachs Alternatives’ growth equity fund, with participation from CapitalG, a venture arm of Alphabet. Previous backers have included Sequoia Capital and Bain Capital Ventures.

Read the complete Bloomberg article here.

Continue Reading

Technology

Here are 4 major moments that drove the stock market last week

Published

on

By

Here are 4 major moments that drove the stock market last week

Continue Reading

Trending